About Intec Pharma

Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill® (AP) platform technology. The Company’s Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism.
Read More

Click the video above to see how Intec’s unique delivery system allows for better absorption in specific applications.

A Novel Drug Delivery System

The Accordion Pill is a drug delivery system that uses biodegradable polymeric films, which combine and load drugs and actives ingredients onto these films, folds them into an undulated shape and then places them inside a capsule. This innovative drug delivery system has a number of unique advantages based on its gastric retentive properties. With AP, drug is released slowly in the stomach over hours, allowing the body to absorb it more steadily. When the pill is done, it simply dissolves in the GI tract.

This novel drug delivery system can improve PK, allows for high drug loading and is ideally suited for compounds with:

  • Narrow Absorption Window
  • Poor solubility
  • Act locally in the stomach or in the upper GI tract

Read More

Latest Press Releases

  • Intec Pharma Announces Pricing of $6.5 Million Public Offering January 30, 2020 JERUSALEM , Jan. 30, 2020 (GLOBE NEWSWIRE) -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announced the pricing of its previously announced underwritten public offering of 16,250,000 ordinary shares (which includes pre-funded warrants to purchase ordinary shares in lieu Continue Reading
  • Intec Pharma Announces Proposed Public Offering January 30, 2020 JERUSALEM , Jan. 30, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announced that it intends to offer and sell a combination of ordinary shares (or pre-funded warrants to purchase ordinary shares in lieu thereof) and warrants to purchase ordinary shares in Continue Reading

Jeffrey A. Meckler, Intec Pharma’s Vice Chairman and CEO, speaks about the Company’s development program in Parkinson’s disease on World Parkinson’s Disease Day 2018.